Accelerating cancer omics and precision oncology in health care and research: a Lancet Oncology Commission.

We have made substantial progress in developing cancer treatments that target specific molecular vulnerabilities in an increasing number of cancer types.1 Interrogation of complex genomic, transcriptomic, and metabolomic (referred to as omics) profiles, integrated with comprehensive clinical data, represents the essential next step to inform the development and application of selective approaches to cancer prevention, diagnosis, and treatment.2 However, the majority of patients with cancer around the world, and particularly those living in resource-limited settings, cannot access molecular testing and targeted therapies due to regulatory, financial, logistical, educational, and clinical barriers.